{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T23:09:02Z","timestamp":1778713742555,"version":"3.51.4"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20220193"],"award-info":[{"award-number":["BK20220193"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2632024ZD02"],"award-info":[{"award-number":["2632024ZD02"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010227","name":"Medical Science and Technology Development Foundation, Nanjing Municipality Health Bureau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010227","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U24A20788"],"award-info":[{"award-number":["U24A20788"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204333"],"award-info":[{"award-number":["82204333"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002857","name":"China Pharmaceutical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.bcp.2026.117904","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T16:03:13Z","timestamp":1773504193000},"page":"117904","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Nigakinone enhances FXR expression to synergize with irinotecan in suppressing colorectal cancer cells and xenografts"],"prefix":"10.1016","volume":"249","author":[{"given":"Yuanyuan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengxia","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengguo","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bcp.2026.117904_b0005","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.bcp.2026.117904_b0010","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"7","key":"10.1016\/j.bcp.2026.117904_b0015","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/CM9.0000000000001474","article-title":"Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020","volume":"134","author":"Cao","year":"2021","journal-title":"Chin. Med. J. (Engl)"},{"issue":"1","key":"10.1016\/j.bcp.2026.117904_b0020","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41572-021-00261-6","article-title":"Liver metastases","volume":"7","author":"Tsilimigras","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"7","key":"10.1016\/j.bcp.2026.117904_b0025","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/jama.2021.0106","article-title":"Diagnosis and treatment of metastatic colorectal cancer: a review","volume":"325","author":"Biller","year":"2021","journal-title":"JAMA"},{"issue":"9138","key":"10.1016\/j.bcp.2026.117904_b0030","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(98)02309-5","article-title":"Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer","volume":"352","author":"Cunningham","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2026.117904_b0035","doi-asserted-by":"crossref","unstructured":"B. Yue, R. Gao, L. Zhao, D. Liu, C. Lv, Z. Wang, F. Ai, B. Zhang, Z. Yu, X. Geng, H. Wang, K. Wang, K. Chen, C. Liu, Z. Wang, W. Dou, beta-Glucuronidase-Expressing Lactobacillus reuteri Triggers Irinotecan Enterotoxicity Through Depleting the Regenerative Epithelial Stem\/Progenitor Pool, Adv. Sci. (Weinh) 12 (26) (2025) e2411052, doi:10.1002\/advs.202411052.","DOI":"10.1002\/advs.202411052"},{"key":"10.1016\/j.bcp.2026.117904_b0040","doi-asserted-by":"crossref","unstructured":"R. Kim, M. Tehfe, P. Kavan, J. Chaves, J.S. Kortmansky, E.X. Chen, C.H. Lieu, L. Wong, M. Fakih, K. Spencer, Q. Zhao, R. Predoiu, C. Li, P. Leconte, D. Adelberg, E.G. Chiorean, Pembrolizumab Plus mFOLFOX7 or FOLFIRI for Microsatellite Stable\/Mismatch Repair-Proficient Metastatic Colorectal Cancer: KEYNOTE-651 Cohorts B and D, Clin. Colorectal Cancer 23 (2) (2024) 118\u2013127 e116, doi:10.1016\/j.clcc.2024.03.001.","DOI":"10.1016\/j.clcc.2024.03.001"},{"issue":"1","key":"10.1016\/j.bcp.2026.117904_b0045","doi-asserted-by":"crossref","first-page":"7255","DOI":"10.1038\/s41467-024-51536-x","article-title":"Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study","volume":"15","author":"Xu","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bcp.2026.117904_b0050","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25010006","article-title":"Targeting Farnesoid X Receptor in Tumor and the Tumor Microenvironment: implication for Therapy","volume":"25","author":"Nenkov","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2026.117904_b0055","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.semcancer.2020.10.003","article-title":"Dietary fat, bile acid metabolism and colorectal cancer","volume":"73","author":"Ocvirk","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bcp.2026.117904_b0060","doi-asserted-by":"crossref","unstructured":"T. Fu, S. Coulter, E. Yoshihara, T.G. Oh, S. Fang, F. Cayabyab, Q. Zhu, T. Zhang, M. Leblanc, S. Liu, M. He, W. Waizenegger, E. Gasser, B. Schnabl, A.R. Atkins, R.T. Yu, R. Knight, C. Liddle, M. Downes, R.M. Evans, FXR Regulates Intestinal Cancer Stem Cell Proliferation, Cell 176 (5) (2019) 1098\u20131112 e1018, doi:10.1016\/j.cell.2019.01.036.","DOI":"10.1016\/j.cell.2019.01.036"},{"issue":"6","key":"10.1016\/j.bcp.2026.117904_b0065","first-page":"445","article-title":"Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study","volume":"4","author":"Trauner","year":"2019","journal-title":"Lancet Gastroenterol."},{"issue":"10215","key":"10.1016\/j.bcp.2026.117904_b0070","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.bcp.2026.117904_b0075","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"New Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bcp.2026.117904_b0080","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41575-020-00404-2","article-title":"The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer","volume":"18","author":"Sun","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.bcp.2026.117904_b0085","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/s41417-020-00239-8","article-title":"Synergistic tumor inhibition of colon cancer cells by nitazoxanide and obeticholic acid, a farnesoid X receptor ligand","volume":"28","author":"Yu","year":"2021","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.bcp.2026.117904_b0090","doi-asserted-by":"crossref","unstructured":"J. Hallin, L.D. Engstrom, L. Hargis, A. Calinisan, R. Aranda, D.M. Briere, N. Sudhakar, V. Bowcut, B.R. Baer, J.A. Ballard, M.R. Burkard, J.B. Fell, J.P. Fischer, G.P. Vigers, Y. Xue, S. Gatto, J. Fernandez-Banet, A. Pavlicek, K. Velastagui, R.C. Chao, J. Barton, M. Pierobon, E. Baldelli, E.F. Patricoin, 3rd, D.P. Cassidy, M.A. Marx, Rybkin, II, M.L. Johnson, S.I. Ou, P. Lito, K.P. Papadopoulos, P.A. Janne, P. Olson, J.G. Christensen, The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients, Cancer Discov. 10 (1) (2020) 54\u201371, doi:10.1158\/2159-8290.CD-19-1167.","DOI":"10.1158\/2159-8290.CD-19-1167"},{"key":"10.1016\/j.bcp.2026.117904_b0095","doi-asserted-by":"crossref","unstructured":"F. Skoulidis, B.T. Li, G.K. Dy, T.J. Price, G.S. Falchook, J. Wolf, A. Italiano, M. Schuler, H. Borghaei, F. Barlesi, T. Kato, A. Curioni-Fontecedro, A. Sacher, A. Spira, S.S. Ramalingam, T. Takahashi, B. Besse, A. Anderson, A. Ang, Q. Tran, O. Mather, H. Henary, G. Ngarmchamnanrith, G. Friberg, V. Velcheti, R. Govindan, Sotorasib for Lung Cancers with KRAS p.G12C Mutation, New Engl. J. Med. 384 (25) (2021) 2371\u20132381, doi:10.1056\/NEJMoa2103695.","DOI":"10.1056\/NEJMoa2103695"},{"issue":"12","key":"10.1016\/j.bcp.2026.117904_b0100","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/j.drudis.2018.06.010","article-title":"Importance of target-mediated drug disposition for small molecules","volume":"23","author":"Smith","year":"2018","journal-title":"Drug Discov. Today"},{"issue":"5676","key":"10.1016\/j.bcp.2026.117904_b0105","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.bcp.2026.117904_b0110","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.bcp.2026.117904_b0115","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/ptr.7588","article-title":"Nigakinone alleviates DSS-induced experimental colitis via regulating bile acid profile and FXR\/NLRP3 signaling pathways","volume":"37","author":"Liu","year":"2023","journal-title":"Phytother. Res."},{"issue":"2","key":"10.1016\/j.bcp.2026.117904_b0120","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2026.117904_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.138493","article-title":"Oral chitosan-cyclodextrin \u201cshell-core\u201d nanoparticles co-loaded Rhein and chlorogenic acid for ulcerative colitis treatment","volume":"288","author":"Nie","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"issue":"18","key":"10.1016\/j.bcp.2026.117904_b0130","doi-asserted-by":"crossref","first-page":"12651","DOI":"10.1021\/acs.jmedchem.2c01737","article-title":"Is Target-based drug discovery efficient? discovery and \u201coff-target\u201d mechanisms of all drugs","volume":"66","author":"Sadri","year":"2023","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2026.117904_b0135","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/s41419-022-04745-5","article-title":"Activation of FXR and inhibition of EZH2 synergistically inhibit colorectal cancer through cooperatively accelerating FXR nuclear location and upregulating CDX2 expression","volume":"13","author":"Yu","year":"2022","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.bcp.2026.117904_b0140","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1038\/s41467-019-10853-2","article-title":"Molecular tuning of farnesoid X receptor partial agonism","volume":"10","author":"Merk","year":"2019","journal-title":"Nat. Commun."},{"issue":"5573","key":"10.1016\/j.bcp.2026.117904_b0145","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1126\/science.1072891","article-title":"A natural product that lowers cholesterol as an antagonist ligand for FXR","volume":"296","author":"Urizar","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.bcp.2026.117904_b0150","doi-asserted-by":"crossref","unstructured":"L. Gandhi, D. Rodriguez-Abreu, S. Gadgeel, E. Esteban, E. Felip, F. De Angelis, M. Domine, P. Clingan, M.J. Hochmair, S.F. Powell, S.Y. Cheng, H.G. Bischoff, N. Peled, F. Grossi, R.R. Jennens, M. Reck, R. Hui, E.B. Garon, M. Boyer, B. Rubio-Viqueira, S. Novello, T. Kurata, J.E. Gray, J. Vida, Z. Wei, J. Yang, H. Raftopoulos, M.C. Pietanza, M.C. Garassino, K.-. Investigators, Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer, New Engl. J. Med. 378 (22) (2018) 2078\u20132092, doi:10.1056\/NEJMoa1801005.","DOI":"10.1056\/NEJMoa1801005"},{"issue":"1","key":"10.1016\/j.bcp.2026.117904_b0155","first-page":"1","article-title":"Combination strategies for first-line treatment of patients with unresectable hepatocellular carcinoma: prospect of natural products","volume":"22","author":"Zhang","year":"2024","journal-title":"Chin. J. Nat. Med."},{"key":"10.1016\/j.bcp.2026.117904_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104398","article-title":"Irinotecan: 25 years of cancer treatment","volume":"148","author":"Bailly","year":"2019","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.117904_b0165","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.apsb.2021.03.043","article-title":"DNA damage repair promotion in colonic epithelial cells by andrographolide downregulated cGAS\u2012STING pathway activation and contributed to the relief of CPT-11-induced intestinal mucositis","volume":"12","author":"Wang","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"issue":"2","key":"10.1016\/j.bcp.2026.117904_b0170","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41419-024-06495-y","article-title":"Farnesoid X receptor promotes non-small cell lung cancer metastasis by activating Jak2\/STAT3 signaling via transactivation of IL-6ST and IL-6 genes","volume":"15","author":"Jin","year":"2024","journal-title":"Cell Death Dis."},{"issue":"10457","key":"10.1016\/j.bcp.2026.117904_b0175","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0140-6736(24)01303-5","article-title":"Primary biliary cholangitis","volume":"404","author":"Tanaka","year":"2024","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.bcp.2026.117904_b0180","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1097\/HEP.0000000000001166","article-title":"Primary biliary cholangitis: personalizing second-line therapies","volume":"82","author":"Levy","year":"2025","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.bcp.2026.117904_b0185","doi-asserted-by":"crossref","DOI":"10.3390\/molecules22020191","article-title":"Silymarin\/Silybin and Chronic Liver Disease: a Marriage of many Years","volume":"22","author":"Federico","year":"2017","journal-title":"Molecules"},{"issue":"11","key":"10.1016\/j.bcp.2026.117904_b0190","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1080\/15563650.2022.2128815","article-title":"Silibinin: a toxicologist's herbal medicine?","volume":"60","author":"Horowitz","year":"2022","journal-title":"Clin. Toxicol. (Phila.)"},{"issue":"6","key":"10.1016\/j.bcp.2026.117904_b0195","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3724\/SP.J.1009.2013.00645","article-title":"Reversing effects of silybin on TAA-induced hepatic CYP3A dysfunction through PXR regulation","volume":"11","author":"Xie","year":"2013","journal-title":"Chin. J. Nat. Med."},{"issue":"3","key":"10.1016\/j.bcp.2026.117904_b0200","doi-asserted-by":"crossref","first-page":"170","DOI":"10.15430\/JCP.2022.27.3.170","article-title":"Silibinin radiosensitizes EGF receptor-knockdown prostate cancer cells by attenuating DNA repair pathways","volume":"27","author":"Rajput","year":"2022","journal-title":"J. Cancer Prev."},{"issue":"4","key":"10.1016\/j.bcp.2026.117904_b0205","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/em.22363","article-title":"Inhibition of urinary bladder cancer cell proliferation by silibinin","volume":"61","author":"Barros","year":"2020","journal-title":"Environ. Mol. Mutagen."},{"issue":"3\u20134","key":"10.1016\/j.bcp.2026.117904_b0210","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.phymed.2012.11.016","article-title":"In vitro and in vivo anti-inflammatory effects of 4-methoxy-5- hydroxycanthin-6-one, a natural alkaloid from Picrasma quassioides","volume":"20","author":"Fan","year":"2013","journal-title":"Phytomedicine"},{"key":"10.1016\/j.bcp.2026.117904_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104043","article-title":"N-methoxy-beta-carboline alkaloids with inhibitory activities against Abeta(42) aggregation and acetylcholinesterase from the stems of Picrasma quassioides","volume":"101","author":"Zhang","year":"2020","journal-title":"Bioorg. Chem."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226002376?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226002376?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T22:17:19Z","timestamp":1778710639000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226002376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":43,"alternative-id":["S0006295226002376"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117904","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nigakinone enhances FXR expression to synergize with irinotecan in suppressing colorectal cancer cells and xenografts","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117904","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117904"}}